Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen

M. Wiedmann; K. Schoppmeyer; H. Witzigmann; J. Hauss; J. Mössner; K. Caca

doi:10.1055/s-2005-858186

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2005; 43(5): 473-475
DOI: 10.1055/s-2005-858186

Corrigendum

Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen

Current Diagnostics and Therapy for Carcinomas of the Bilary Tree and GallbladderM. Wiedmann¹ , K. Schoppmeyer¹ , H. Witzigmann² , J. Hauss² , J. Mössner¹ , K. Caca¹

¹Medizinische Klinik II, Universität Leipzig
²Chirurgische Klinik II, Universität Leipzig

Abstract

Volltext

Referenzen

Literatur

1 Broden G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand Suppl. 1980; 500 7-12
2 Lowenfels A B, Norman J. Isoniazid and bile duct cancer. Jama. 1978; 240 434-435
3 Ellis E F, Gordon P R and Gottlieb LS. Oral contraceptives and cholangiocarcinoma. Lancet. 1978; 1 207
4 Strom B L, Soloway R D, Rios-Dalenz J L. et al . Risk factors for gallbladder cancer: an international collaborative case-control study. Cancer. 1995; 76 1747-1756
5 Bergquist A, Glaumann H, Persson B. et al . Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 1998; 27 311-316
6 Watanapa P, Watanapa W B. Liver fluke-associated cholangiocarcinoma. Br J Surg. 2002; 89 962-970
7 Parkin D M, Srivatanakul P, Khlat M. et al . Liver cancer in Thailand: a case-control study of cholangiocarcinoma. Int J Cancer. 1991; 48 323-328
8 Shin H R, Lee C U, Park H J. et al . Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol. 1996; 25 933-940
9 Donato F, Gelatti U, Tagger A. et al . Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001; 12 959-964
10 Kobayashi M, Ikeda K, Saitoh S. et al . Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000; 88 2471-2477
11 Yoshida T, Sugai T, Habano W. et al . Microsatellite instability in gallbladder carcinoma: two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol. 2000; 35 768-774
12 Han C, Demetris A J, Wu T. Cyclooxygenase-2 and prostaglandin E2 promote cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of epidermal growth factor receptor and AKT. Hepatology. 2004; 40 301A, abstract 318
13 Heinrich P C, Behrmann I, Haan S. et al . Principles of interleukin (IL)- 6-type cytokine signalling and its regulation. Biochem J. 2003; 374 1-20
14 Satyanarayana A, Manns M P, Rudolph K L. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004; 40 276-283
15 Benckert C, Jonas S, Cramer T. et al . Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003; 63 1083-1092
16 Ogasawara S, Yano H, Higaki K. et al . Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res. 2001; 20 97-113
17 Maeda T, Sepe P, Lahousse S. et al . Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol. 2003; 38 615-622
18 Maeda T, Taguchi K, Aishima S. et al . Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev. 2004; 28 313-318
19 Ince N, de la Monte S M, Wands J R. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res. 2000; 60 1261-1266
20 Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology. 1996; 23 1341-1344
21 Tanaka S, Sugimachi K, Kameyama T. et al . Human WISP1 v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology. 2003; 37 1122-1129
22 Fujita N, Noda Y, Kobayashi G. et al . Diagnosis of the depth of invasion of gallbladder carcinoma by EUS. Gastrointest Endosc. 1999; 50 659-663
23 Sadamoto Y, Kubo H, Harada N. et al . Preoperative diagnosis and staging of gallbladder carcinoma by EUS. Gastrointest Endosc. 2003; 58 536-541
24 Fritscher-Ravens A, Broering D C, Knoefel W T. et al . EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol. 2004; 99 45-51
25 Sakamoto E, Nimura Y, Hayakawa N. et al . The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998; 227 405-411
26 Pitt H A, Nakeeb A, Abrams R A. et al . Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg. 1995; 221 788-797, discussion 797 - 798
27 Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer. 1998; 34 977-986
28 Gerhards M F, van Gulik T M, Gonzalez D. et al . Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003; 27 173-179
29 Todoroki T, Kawamoto T, Koike N. et al . Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg. 2000; 87 306-313
30 Verbeek P C, Van Leeuwen D J, Van Der Heyde M N. et al . Does additive radiotherapy after hilar resection improve survival of cholangiocarcinoma? An analysis in sixty-four patients. Ann Chir. 1991; 45 350-354
31 Cameron J L, Pitt H A, Zinner M J. et al . Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990; 159 91-97, discussion 97 - 98
32 Bouras N, Caudry M, Saric J. et al . Conformal therapy of locally advanced cholangiocarcinoma of the main bile ducts. Cancer Radiother. 2002; 6 22-29
33 Serafini F M, Sachs D, Bloomston M. et al . Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg. 2001; 67 839-843, discussion 843 - 844
34 Wiedmann M, Dietrich A, Mossner J. et al . Combined percutaneous transhepatic biliary drainage with port implantation for management of patients with malignant biliary obstruction. Gastrointest Endosc. 2004; 60 117-120
35 Freeman M L, Overby C. Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc. 2003; 58 41-49
36 Hintze R E, Abou-Rebyeh H, Adler A. et al . Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc. 2001; 53 40-46
37 De Palma G D, Pezzullo A, Rega M. et al . Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study. Gastrointest Endosc. 2003; 58 50-53
38 Burmester E, Niehaus J, Leineweber T. et al . EUS-cholangio-drainage of the bile duct: report of 4 cases. Gastrointest Endosc. 2003; 57 246-251
39 Prat F, Lafon C, De Lima D M. et al . Endoscopic treatment of cholangiocarcinoma and carcinoma of the duodenal papilla by intraductal high-intensity US: results of a pilot study. Gastrointest Endosc. 2002; 56 909-915
40 Taal B G, Audisio R A, Bleiberg H. et al . Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma: an EORTC gastrointestinal tract cancer cooperative group study. Ann Oncol. 1993; 4 607-609
41 Okada S, Ishii H, Nose H. et al . A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology. 1994; 51 515-517
42 Falkson G, MacIntyre J M, Moertel C G. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984; 54 965-969
43 Choi C W, Choi I K, Seo J H. et al . Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000; 23 425-428
44 Chen J S, Jan Y Y, Lin Y C. et al . Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs. 1998; 9 393-397
45 Raderer M, Hejna M H, Valencak J B. et al . Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999; 56 177-180
46 Penz M, Kornek G V, Raderer M. et al . Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001; 12 183-186
47 Pazdur R, Royce M E, Rodriguez G I. et al . Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol. 1999; 22 78-81
48 Papakostas P, Kouroussis C, Androulakis N. et al . First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract: a multicentre phase II study. Eur J Cancer. 2001; 37 1833-1838
49 Jones D V Jr, Lozano R, Hoque A. et al . Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol. 1996; 14 2306-2310
50 Sanz-Altamira P M, O’Reilly E, Stuart K E. et al . A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol. 2001; 12 501-504
51 Chen J S, Yang T S, Lin Y C. et al . A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J Clin Oncol. 2003; 33 353-356
52 Kubicka S, Rudolph K L, Tietze M K. et al . Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001; 48 783-789
53 Ueno H, Okusaka T, Ikeda M. et al . Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004; 91 1769-1774
54 Alden M E, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys. 1994; 28 945-951
55 Eschelman D J, Shapiro M J, Bonn J. et al . Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology. 1996; 200 717-724
56 Morganti A G, Trodella L, Valentini V. et al . Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys. 2000; 46 913-919
57 Urego M, Flickinger J C, Carr B I. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 1999; 44 121-126
58 Nomura M, Yamakado K, Nomoto Y. et al . Clinical efficacy of brachytherapy combined with external-beam radiotherapy and repeated arterial infusion chemotherapy in patients with unresectable extrahepatic bile duct cancer. Int J Oncol. 2002; 20 325-331
59 Malik I A, Aziz Z, Zaidi S H. et al . Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol. 2003; 26 174-177
60 Doval D C, Sekhon J S, Gupta S K. et al . A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer. 2004; 90 1516-1520

Dr. med. Marcus Wiedmann

Medizinische Klinik II, Universität Leipzig

Philipp-Rosenthal-Str. 27

04103 Leipzig

Telefon: 03 41/9 71 22 25

Fax: 03 41/9 71 22 39

eMail: wiedm@medizin.uni-leipzig.de